Consultation Document Draft Report Project Number HT0038-000 Call for feedback Thu, 03/07/2024 - 00:01 Feedback Due By Thu, 03/21/2024 - 23:59 Project Line Health Technology Review Webform Node Alemtuzumab, Cladribine, Fingolimod, and Natalizumab as First-Line Treatments in Adult Patients With Highly Active Relapsing Multiple Sclerosis - Draft Science Report - HT0038 Status message Sorry… This form is closed to new submissions.
Alemtuzumab, Cladribine, Fingolimod, and Natalizumab as First-Line Treatments in Adult Patients With Highly Active Relapsing Multiple Sclerosis - Draft Science Report - HT0038 Status message Sorry… This form is closed to new submissions.
